NCT02688881View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors

PHASE4CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 5, 2017

Primary Completion Date

December 30, 2020

Study Completion Date

February 24, 2021

Conditions
Refractory Solid Tumors
Interventions
DRUG

sirolimus

Rapamune

Trial Locations (1)

99999

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02688881 - Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter